Oxytocin in MRI-HIFU

Turku University Hospital (TYKS)

Status and phase: Unknown; Phase 4

Conditions: Adenomyosis; Fibroid

Treatments: Drug: Oxytocin

Study type: Interventional

Funder types: Other

Identifiers

NCT03937401

T366/2017

Details and patient eligibility

About

Capability of oxytocin in improving the efficacy of MRI-HIFU is studied. Patients undergoing MRI-HIFU treatment are given oxytocin during treatment and the efficacy of the treatment will be analysed by patient reported symptom questionnaires and imaging data.

Enrollment: 100 estimated patients

Sex: Female

Ages: 18 to 50 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Patients undergoing MRI-HIFU -treatment
• Patients assessed for suitability to MRI-HIFU treatment
• willingness to participate in trial

Exclusion criteria

• Known allergy to Syntocinon/oxytocin
• Elevated blood pressure
• ischemic heart disease
• Long QT- interval

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

Patients treated with oxytocin during MRI-HIFU

Experimental group

Treatment:

Drug: Oxytocin